Liver x receptor modulators

Abstract

Provided herein are novel compounds and pharmaceutically acceptable salts thereof that are liver X receptor modulators. Also provided are compositions comprising compounds of the invention and a carrier. Additionally, use of the compounds herein and methods for treating a disease or disorder associated with the liver X receptor are further described.

1 . A compound represented by the following structural formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein:
 X is N or CR c ; 
 R 1  is alkyl or —NR a R b ; 
 R 2  is H; halogen; —CN; —NRC(O)R; —C(O)OR; —C(O)NR a R b ; monocyclic heteroaromatic optionally substituted with one or more groups selected from alkyl, —CN, —NRC(O)R, —C(O)OR, —C(O)NR a R b  and halogen; monocyclic non-aromatic heterocycle optionally substituted with one or more groups selected from alkyl, halogen, —CN and ═O; or alkyl optionally substituted by one or more groups selected from halogen, hydroxy, alkoxy, —NR a R b , —NRC(O)R, —NRC(O)O(alkyl), —NRC(O)N(R) 2 , —C(O)OR, thiol, alkylthiol, nitro, —CN, ═O, —OC(O)H, —OC(O)(alkyl), —OC(O)O(alkyl), —OC(O)N(R) 2  and —C(O)NR a R b ; 
 R 3  is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, monocyclic non-aromatic heterocycle, monocyclic heteroaromatic or phenyl, wherein the phenyl, monocyclic non-aromatic heterocycle and monocyclic heteroaromatic group represented by R 3  are optionally substituted with one or more groups selected from alkyl, halogen, haloalkyl, alkoxy, haloalkoxy, nitro and —CN; 
 R 4  and R 5  independently are halogen, —CN, —OR, —SR, —N(R) 2 , —C(O)R, —C(O)OR, —OC(O)O(alkyl), —C(O)O(haloalkyl), —OC(O)R, —C(O)N(R) 2 , —OC(O)N(R) 2 , —NRC(O)R, —NRC(O)O(alkyl), —S(O)R, —SO 2 R, —SO 2 N(R) 2 , —NRS(O)R, —NRSO 2 R, —NRC(O)N(R) 2 , —NRSO 2 N(R) 2 , haloalkyl, haloalkoxy, cycloalkoxy, cycloalkyl, monocyclic non-aromatic heterocycle, monocyclic heteroaromatic or alkyl, wherein the alkyl, monocyclic non-aromatic heterocycle and monocyclic heteroaromatic group represented by R 4  or R 5  are optionally substituted with one or more groups selected from —CN, —OR, —SR, —N(R) 2 , ═O, —C(O)R, —C(O)OR, —C(O)O(haloalkyl), —OC(O)R, —OC(O)O(alkyl), —C(O)N(R) 2 , —OC(O)N(R) 2 , —NRC(O)R, —NRC(O)O(alkyl), —S(O)R, —SO 2 R, —SO 2 N(R) 2 , —NRS(O)R, —NRSO 2 R, —NRC(O)N(R) 2  and —NRSO 2 N(R) 2 ; 
 R 6  is H, halogen, —CN, —OR, —SR, —N(R) 2 , —C(O)R, —C(O)OR, —OC(O)O(alkyl), —C(O)O(haloalkyl), —OC(O)R, —C(O)N(R) 2 , —OC(O)N(R) 2 , —NRC(O)R, —NRC(O)O(alkyl), —S(O)R, —SO 2 R, —SO 2 N(R) 2 , —NRS(O)R, —NRSO 2 R, —NRC(O)N(R) 2 , —NRSO 2 N(R) 2 , haloalkyl, haloalkoxy, cycloalkoxy, cycloalkyl or alkyl, wherein the alkyl group represented by R 6  is optionally substituted with one or more groups selected from —CN, —OR, —SR, —N(R) 2 , ═O, —C(O)R, —C(O)OR, —C(O)O(haloalkyl), —OC(O)R, —OC(O)O(alkyl), —C(O)N(R) 2 , —OC(O)N(R) 2 , —NRC(O)R, —NRC(O)O(alkyl), —S(O)R, —SO 2 R, —SO 2 N(R) 2 , —NRS(O)R, —NRSO 2 R, —NRC(O)N(R) 2  and —NRSO 2 N(R) 2 ; or 
 R 5  and R 6 , taken together with the carbon atoms to which they are bonded, form a monocyclic non-aromatic heterocycle optionally substituted with one or more groups selected from alkyl, halogen, hydroxyalkyl, alkoxyalkyl, haloalkyl and ═O; and 
 each R independently is H or alkyl; 
 R a  and R b  are independently H, alkyl or R a  and R b  can be taken together with the nitrogen to which they are attached to form a monocyclic non-aromatic heterocycle; and 
 R c  is H, alkyl, or halogen. 
 
     
     
         2 . The compound of  claim 1 , wherein:
 R 3  is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, or phenyl, wherein the phenyl group represented by R 3  is optionally substituted with one or more groups selected from alkyl, halogen, haloalkyl, alkoxy, haloalkoxy, nitro and —CN;   R 4  and R 5  independently are halogen, —CN, —OR, —SR, —N(R) 2 , —C(O)R, —C(O)OR, —OC(O)O(alkyl), —C(O)O(haloalkyl), —OC(O)R, —C(O)N(R) 2 , —OC(O)N(R) 2 , —NRC(O)R, —NRC(O)O(alkyl), —S(O)R, —SO 2 R, —SO 2 N(R) 2 , —NRS(O)R, —NRSO 2 R, —NRC(O)N(R) 2 , —NRSO 2 N(R) 2 , haloalkyl, haloalkoxy, cycloalkoxy, cycloalkyl or alkyl, wherein the alkyl represented by R 4  or R 5  is optionally substituted with one or more groups selected from —CN, —OR, —SR, —N(R) 2 , ═O, —C(O)R, —C(O)OR, —C(O)O(haloalkyl), —OC(O)R, —OC(O)O(alkyl), —C(O)N(R) 2 , —OC(O)N(R) 2 , —NRC(O)R, —NRC(O)O(alkyl), —S(O)R, —SO 2 R, —SO 2 N(R) 2 , —NRS(O)R, —NRSO 2 R, —NRC(O)N(R) 2  and —NRSO 2 N(R) 2 ;   R 6  is H, halogen, —CN, —OR, —SR, —N(R) 2 , —C(O)R, —C(O)OR, —OC(O)O(alkyl), —C(O)O(haloalkyl), —OC(O)R, —C(O)N(R) 2 , —OC(O)N(R) 2 , —NRC(O)R, —NRC(O)O(alkyl), —S(O)R, —SO 2 R, —SO 2 N(R) 2 , —NRS(O)R, —NRSO 2 R, —NRC(O)N(R) 2 , —NRSO 2 N(R) 2 , haloalkyl, haloalkoxy, cycloalkoxy, cycloalkyl or alkyl, wherein the alkyl group represented by R 6  is optionally substituted with one or more groups selected from —CN, —OR, —SR, —N(R) 2 , ═O, —C(O)R, —C(O)OR, —C(O)O(haloalkyl), —OC(O)R, —OC(O)O(alkyl), —C(O)N(R) 2 , —OC(O)N(R) 2 , —NRC(O)R, —NRC(O)O(alkyl), —S(O)R, —SO 2 R, —SO 2 N(R) 2 , —NRS(O)R, —NRSO 2 R, —NRC(O)N(R) 2  and —NRSO 2 N(R) 2 .   
     
     
         3 . The compound of  claim 2 , wherein the compound is represented by the following structural formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         4 . The compound of  claim 3 , wherein the compound is represented by the following structural formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         5 . The compound of  claim 4 , wherein the compound is represented by the following structural formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         6 . The compound of  claim 5 , wherein the compound is represented by the following structural formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         7 . The compound of  claim 4 , wherein the compound is represented by the following structural formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         8 . The compound of  claim 7 , wherein the compound is represented by the following structural formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         9 . The compound of  claim 8 , wherein:
 R 1  is methyl or —NH 2 ;   R 2  is H or methyl, wherein the methyl group represented by R 2  is optionally substituted with one or more groups selected from halogen, hydroxy, alkoxy, —NR a R b , —NRC(O)R, —NRC(O)O(alkyl), —NRC(O)N(R) 2 , —C(O)OR, thiol, alkylthiol, nitro, —CN, ═O, —OC(O)H, —OC(O)(alkyl), —OC(O)O(alkyl), —C(O)NR a R b  and —OC(O)N(R) 2 ;   R 3  is methyl, ethyl, propyl, isopropyl, tert-butyl, sec-butyl, iso-butyl, —CH 2 CF 3 , —CH(CH 2 F) 2 , —CH(CHF 2 ) 2 , —CH(CF 3 ) 2 , —CF(CH 3 ) 2 , —CF 3 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, —C(OH)(CH 3 ) 2 , —CH(OH)(CH 3 ), or   phenyl, wherein the phenyl group represented by R 3  is optionally substituted with one or more groups selected from alkyl, halogen, haloalkyl, alkoxy, haloalkoxy, nitro and —CN; and   R c , where present, is H.   
     
     
         10 . The compound of  claim 9 , wherein R 2  is H or —CH 2 OH. 
     
     
         11 . The compound of  claim 10 , wherein:
 R 1  is methyl;   R 2  is —CH 2 OH; and   R 3  is isopropyl.   
     
     
         12 . The compound of  claim 11 , wherein R 4  and R 5  independently are halogen, hydroxy, alkyl, cycloalkyl, cycloalkoxy, alkoxy, haloalkoxy, haloalkyl, —N(R) 2 , —C(O)OH, —C(O)O(alkyl), —C(O)O(haloalkyl), —C(O)(alkyl), —C(O)N(R) 2 , —NRC(O)R, —SO 2 N(R) 2 , —OC(O)N(R) 2 , —CN, hydroxyalkyl or dihydroxyalkyl. 
     
     
         13 . The compound of  claim 12 , wherein R 4  and R 5  independently are methyl, ethyl, hydroxy, CF 3 , isopropyl, cyclopropyl, —CH 2 OH, —CH(OH)(CH 2 )(OH), —C(OH)(CH 3 ) 2 , —CH(OH)(CH 3 ), —CH(OH)(CH 2 )(CH 3 ), —CH(OH)(CH 2 ) 2 (CH 3 ), —C(O)NH 2 , —C(O)N(CH 3 ) 2 , —C(O)OH, —C(O)NH(CH 3 ), —C(O)CH 3 , —C(O)CH 2 CH 3 , —C(O)O(CH 2 )(CH 3 ), —C(O)O(tert-butyl), —C(O)O(C)(CH 3 ) 2 (CF 3 ), —NHC(O)CH 3 , —OCHF 2 , —OCF 3 , —OCH 2 CH 3 , —OCH(CH 3 ) 2  or —OCH 3 . 
     
     
         14 . The compound of  claim 13 , wherein R 4  is alkyl, haloalkyl, cycloalkyl, alkoxy, or haloalkoxy. 
     
     
         15 . The compound of  claim 14 , wherein R 4  is methyl, halogenated methyl, cyclopropyl, —OCHF 2  or —OCH 3 . 
     
     
         16 . The compound of  claim 15 , wherein R 4  is CF 3 . 
     
     
         17 . The compound of  claim 16 , where R 5 —C(OH)(CH 3 ) 2 . 
     
     
         18 . The compound of  claim 1 , wherein the compound is represented by a structural formula selected from 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         19 . A pharmaceutical composition comprising a pharmaceutical carrier or diluent and the compound of  claim 1 . 
     
     
         20 . A method of treating a subject with a disease or disorder that is treatable by upregulating LXR activity comprising administering an effective amount of the compound of  claim 1  to the subject. 
     
     
         21 - 23 . (canceled) 
     
     
         24 . A compound represented by the following structural formula: 
       
         
           
           
               
               
           
         
         or a salt thereof, wherein: 
         X is N or CR c ; 
         R 10  is alkyl or —NR a R b ; 
         R 20  is H; halogen; —CN; —NRC(O)R; —C(O)OR; —C(O)NR a R b ; monocyclic heteroaromatic optionally substituted with one or more groups selected from alkyl, —CN, —NRC(O)R, —C(O)OR, —C(O)NR a R b  and halogen; monocyclic non-aromatic heterocycle optionally substituted with one or more groups selected from alkyl, halogen, —CN and ═O; or alkyl optionally substituted by one or more groups selected from halogen, hydroxy, alkoxy, —NR a R b , —NRC(O)R, —NRC(O)O(alkyl), —NRC(O)N(R) 2 , —C(O)OR, thiol, alkylthiol, nitro, —CN, ═O, —OC(O)H, —OC(O)(alkyl), —OC(O)O(alkyl), —OC(O)N(R) 2 , —C(O)NR a R b , and —O(protecting group); 
         R 30  is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl or phenyl, wherein the phenyl group represented by R 30  is optionally substituted with one or more groups selected from alkyl, haloalkyl, alkoxy, haloalkoxy, nitro and —CN; 
         each R independently is H or alkyl; 
         R a  and R b  are independently H, alkyl or R a  and R b  can be taken together with the nitrogen to which they are attached to form a monocyclic non-aromatic heterocycle; and 
         R c  is H, alkyl, or halogen. 
       
     
     
         25 - 32 . (canceled)